Wedbush analysts have weighed in on Staar Surgical's recent slowdown in China, arguing the issue is more about consumers' wallets than competition from laser eye surgery. The investment bank said affordability pressures are weighing on demand for the company's implantable collamer lenses (ICLs) in China, while US growth remains constrained by a lengthy surgeon-training process.
What's Behind the China Slowdown?
Staar Surgical sells ICLs, a vision-correction option that patients typically pay for out of pocket. Unlike laser procedures, ICLs are implanted inside the eye and can be removed or replaced. Wedbush's analysis suggests that when Chinese household budgets tighten, people postpone elective procedures like ICL implantation rather than switching to alternatives. This is a different problem than losing market relevance—it implies demand could rebound if consumer spending improves.
The broader economic backdrop in China supports this view. Recent data showed China's Q2 GDP missed targets, and June bank lending also fell short of expectations, reflecting a slowing economy. Consumer confidence has been fragile, and big-ticket, optional healthcare spending is often the first to be cut when budgets tighten.
Wedbush also noted that Staar benefits from a "reputational moat" for its EVO lens, which helps protect its market position. However, the bank flagged a growing threat from local rival EyeBright, which could chip away at market share over the next couple of years.
US Growth Capped by Training Pipeline
In the United States, the challenge is different. Wedbush said the issue is less about demand and more about capacity. Surgeons need multi-year training before they can routinely perform ICL implants, so sales cannot ramp up quickly even if interest rises. This acts like a speed limit on US growth, meaning any pickup in demand won't immediately translate into higher unit sales.
Staar Surgical has been working to expand its training programs, but the process is inherently slow. The company needs to build a pipeline of trained surgeons, which takes time and investment.
What It Means for Investors
Wedbush maintained its outperform rating and $40 price target on Staar Surgical shares, which were trading around $27.94 at the time of the report. The gap between the target and the current price reflects how much improvement investors expect in China's spending backdrop, plus steady progress in building US surgical capacity.
If China's softness is mainly an affordability story, Staar's results may track consumer confidence more than competition. Volumes can drop fast when people delay big-ticket, optional healthcare, and they can recover just as quickly when budgets loosen. That makes revenue more sensitive to swings in spending conditions.
Meanwhile, the multi-year training pipeline in the US acts as a constraint. Even a demand pickup won't immediately show up in unit sales if there aren't enough trained surgeons to perform the procedures. Investors will likely watch for signs of improving consumer sentiment in China and updates on surgeon training progress in the US.
For everyday investors, the key takeaway is that Staar Surgical's near-term performance hinges on two factors: whether Chinese consumers start spending again on elective procedures, and how quickly the company can expand its US surgeon base. Neither is guaranteed, but both are within the company's control to some degree.
